Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05893498 · ClinicalTrials.gov registry record · NA
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
A NA study of Percutaneous Coronary Intervention, sponsored by CathWorks.
- Active
- Registry status
- NA
- Development phase
- 1,924
- Enrollment target
- 20
- Study locations
NCT05893498: Active NA study of Percutaneous Coronary Intervention, sponsored by CathWorks.
NCT05893498 is a NA study of Percutaneous Coronary Intervention that is active but no longer recruiting, run by CathWorks. The registered enrollment target is 1,924 participants, below the 5,065-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05893498, a NA study of Percutaneous Coronary Intervention, is active but no longer recruiting, sponsored by CathWorks.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,924 participants
- Enrollment target
- 20
- Study locations
Study Summary
To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
Primary Outcome
Rate of the composite of all-cause death, myocardial infarction (MI) or unplanned clinically-driven revascularization
Conditions Studied
Interventions
- DEVICE FFRangio
- DEVICE FFR or NHPR
Study Locations (20)
California
- University of California San Diego Health - La Jolla
- VA- Long Beach Healthcare - Long Beach
- Keck Medicine of USC - Los Angeles
- UCLA Medical Center - Los Angeles
- Stanford University - Palo Alto
- VA - Palo Alto Healthcare - Palo Alto
- Kaiser Permanente San Francisco - San Francisco
- St. Joesph's Medical Center - Stockton
Florida
- HCA Florida JFK Hospital - Atlantis
- Cardiac & Vascular Institute - Gainesville
- University of Miami - Miami
- HCA Florida Northside Hospital - St. Petersburg
- Tallahassee Research Institute - Tallahassee
- University of South Florida - Tampa
Kansas
- Ascension Via Christi St. Francis - Wichita
- Kansas Heart Hospital - Wichita
Georgia
- Archbold Hospital - Thomasville
Illinois
- Carle Foundation Hospital - Urbana
Kentucky
- St. Elizabeth Healthcare - Edgewood
Maryland
- Medstar Union Memorial Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,924 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT05893498 still lists
NCT05893498 is an interventional study that assigns participants to a tested intervention. Its 1,924 participants enrollment target places it among the larger protocols in the corpus, below the 5,065-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 2 interventions - of which FFRangio is the first listed.
NCT05893498 names 20 study sites across 7 states, led by California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05893498 about?
NCT05893498 is a clinical study titled "Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment". To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
What is the current status of trial NCT05893498?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,924 participants. The study started on 2023-06-21. Estimated completion is 2026-05.
What conditions does trial NCT05893498 study?
This clinical trial studies the following conditions: Percutaneous Coronary Intervention.
What interventions are being tested in trial NCT05893498?
The interventions under investigation include: FFRangio (DEVICE), FFR or NHPR (DEVICE).
Who is sponsoring clinical trial NCT05893498?
This trial is sponsored by CathWorks, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05893498 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Percutaneous Coronary Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05893498's enrollment target sits among peer trials
1,924 5th of 12 higher than 8 of 12 other Percutaneous Coronary Intervention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Percutaneous Coronary Intervention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise Prescription in Cardiac Rehabilitation
COMPLETED · NA
-
Enhancing Cardiac Rehabilitation Through Behavioral Nudges
COMPLETED · NA
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RECRUITING · Phase 4
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI